Interleukin 2 (IL-2) is the only systemic treatment currently available that is capable of curing patients with metastatic renal cell cancer (RCC). The first indications that IL-2 could mediate ...

In a clinical trial conducted by experts in the metastatic clear cell renal cell carcinoma (ccRCC) — a type of kidney cancer — treatment space, investigators highlighted the importance of tailoring ...

The study emphasizes the need for further research to make exceptional responses more common in RCC treatment. In patients with RCC, exceptional response to immunotherapy may be related to clonal ...